Slideshow
Author(s):
Pain related to more severe motor symptoms, phosphodiesterase 10A loss seen early, novel therapy shows promise, and other recent findings are summarized here.
Parkinson Agent Prasinezumab Misses Primary End Point But Shows Positive Effects in Other Outcomes
Episode 126: Exploring the Therapeutic Potential of ATH434 in Multiple System Atrophy
Tavapadon Meets Primary and Secondary End Points in Phase 3 TEMPO-2 Trial for Early Parkinson Disease
Episode 119: Utilizing the Syn-One Test to Diagnose Parkinson Disease
APOE4 Allele Carriers and Parkinson Disease Named Among Highest Risk Factors for Epilepsy in Patients With Dementia
System Integration: How AI Is Weaving Itself into Neurology